Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Therapy vs Pentoxyphilline in Severe Alcoholic Hepatitis
NCT02458079Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Dec 2014
- Primary completion
- Jul 2016
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, open-label trial of allogeneic fecal microbiota in alcoholic hepatitis (AH) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Survival at 3 months. Started Dec 2014; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT02458079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02458079.